Immuno-Oncology Biotechnology Company Salspera(TKVA.US) US Stock IPO Priced at $14 to $16 per share, planning to raise $85 million

LootboxPhobia · 2026-02-24T15:20:29+00:00

Salspera plans to go public on NASDAQ, issuing 57 million shares to raise $85 million, with an offering price of $14 to $16 per share. The company is dedicated to developing "living biopharmaceuticals," primarily targeting pancreatic cancer. Its lead project, Saltikva, is a genetically modified Salmonella typhimurium.

LootboxPhobia

2026-02-24 15:20:29

Abstract generation in progress

The Tong Finance APP has learned that Salspera (TKVA.US), a clinical-stage cancer biotechnology company focused on developing live biological drugs to stimulate immune responses, disclosed its initial public offering (IPO) terms on Monday.

The Massachusetts-based company plans to raise $85 million by issuing 5.7 million shares at a price range of $14 to $16 per share.

Salspera aims to develop a new class of immunotherapy for treating solid tumors, which it calls “live biological drugs,” genetically engineered biologics capable of expressing specific anti-tumor factors within the tumor microenvironment.

Its lead product, Saltikva, is a genetically attenuated strain of Salmonella typhimurium, non-toxic and orally administered. This engineered strain expresses the interleukin-2 gene (Salmonella-IL2), which may help increase the number of NK cells and CD8+ cytotoxic T cells in the tumor microenvironment and peripheral blood. The company is currently targeting pancreatic cancer and has completed a Phase II trial in patients with Stage IV metastatic pancreatic cancer.

Salspera was founded in 2017 and plans to list on NASDAQ under the ticker TKVA. Kingswood Capital Markets is serving as the exclusive bookrunner for the offering.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.